following a full submission assessed under the ultra-orphan medicine process:
crizotinib (Xalkori®) is accepted for use within NHSScotland.
Indication under review: treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).
In a small, single arm, open-label, phase I study of patients with advanced ROS1-positive NSCLC, treatment with crizotinib resulted in an objective response in 70% of patients.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of crizotinib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice161KB (PDF)
- Medicine name:
- crizotinib (Xalkori)
- SMC ID:
- Treatment of adults with ROS1-positive advanced non-small cell lung cancer.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 11 June 2018